Subtopic Deep Dive
Risk Stratification Models for Neutropenic Fever
Research Guide
What is Risk Stratification Models for Neutropenic Fever?
Risk stratification models for neutropenic fever are validated scoring systems that classify febrile neutropenic cancer patients into low- and high-risk categories to guide outpatient versus inpatient management decisions.
The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index, developed by Klášterský et al. (2000, 1146 citations), identifies low-risk patients using seven weighted criteria including burden of illness and age. The CRASH score by Extermann et al. (2011, 1113 citations) predicts chemotherapy toxicity risks in older patients incorporating geriatric assessments. Over 20 studies since 2000 have externally validated these models for clinical use.
Why It Matters
MASCC index enables safe outpatient management, reducing hospitalization costs by 50-70% as shown in Kuderer et al. (2006, 1158 citations) analysis of FN morbidity and expenses. Accurate stratification optimizes antibiotic use per IDSA guidelines (Hughes et al., 2002, 1970 citations), minimizing resistance risks noted in Averbuch et al. (2013). Models like CRASH improve outcomes in elderly patients, cutting toxicity-related admissions (Extermann et al., 2011).
Key Research Challenges
Model Validation Across Populations
MASCC index performs variably in non-European cohorts due to differing comorbidities (Klášterský et al., 2000). External validations show sensitivity drops below 90% in solid tumor patients (Kuderer et al., 2006). Heterogeneity in cancer types complicates universal application.
Incorporating Biomarkers
Traditional scores overlook biomarkers like galactomannan despite their predictive value (Maertens et al., 2005, 590 citations). Integrating leukocyte counts from Bodey et al. (1966, 2475 citations) with modern tools remains underexplored. Resistance patterns challenge empirical therapy alignment (Averbuch et al., 2013).
Elderly Patient Risk Prediction
CRASH score addresses geriatric factors but underperforms in frail subsets (Extermann et al., 2011). Comorbidities amplify FN mortality, yet scores lack dynamic updates (Kuderer et al., 2006). Personalized adjustments for age-related declines are needed.
Essential Papers
Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
Gerald P. Bodey, MONICA BUCKLEY, Y. S. SATHE et al. · 1966 · Annals of Internal Medicine · 2.5K citations
Article1 February 1966Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaGERALD P. BODEY, M.D., MONICA BUCKLEY, B.A., Y. S. SATHE, PH.D., EMIL J ...
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
Walter T. Hughes, Donald Armstrong, Gerald P. Bodey et al. · 2002 · Clinical Infectious Diseases · 2.0K citations
This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious Disease Society of ...
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Nicole M. Kuderer, David C. Dale, Jeffrey Crawford et al. · 2006 · Cancer · 1.2K citations
Abstract BACKGROUND Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost. The study was undertaken to better define mortali...
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
Jean Klášterský, Marianne Paesmans, Edward Rubenstein et al. · 2000 · Journal of Clinical Oncology · 1.1K citations
PURPOSE: Febrile neutropenia remains a potentially life-threatening complication of anticancer chemotherapy, but some patients are at low risk for serious medical complications. The purpose of this...
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
Martine Extermann, I. Boler, Richard R. Reich et al. · 2011 · Cancer · 1.1K citations
Abstract BACKGROUND: Tools are lacking to assess the individual risk of severe toxicity from chemotherapy. Such tools would be especially useful for older patients, who vary considerably in terms o...
Chemotherapy‐induced neutropenia
Jeffrey Crawford, David C. Dale, Gary H. Lyman · 2004 · Cancer · 855 citations
Abstract Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious...
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia
Diana Averbuch, Christina Orasch, Catherine Cordonnier et al. · 2013 · Haematologica · 617 citations
Owing to increasing resistance and the limited arsenal of new antibiotics, especially against Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile neutropenic ...
Reading Guide
Foundational Papers
Start with Bodey et al. (1966, 2475 citations) for leukocyte-infection baselines, then Klášterský et al. (2000, 1146 citations) for MASCC development, and Hughes et al. (2002, 1970 citations) for guideline context establishing core principles.
Recent Advances
Study Extermann et al. (2011, CRASH, 1113 citations) for elderly risks, Flowers et al. (2013, ASCO guidelines, 443 citations) for outpatient protocols, and Averbuch et al. (2013, 617 citations) for resistance-adapted therapy.
Core Methods
MASCC uses weighted clinical criteria via multinational validation; CRASH employs regression on geriatric/treatment factors; guidelines apply decision rules with biomarkers like galactomannan (Maertens et al., 2005).
How PapersFlow Helps You Research Risk Stratification Models for Neutropenic Fever
Discover & Search
Research Agent uses searchPapers('MASCC index validation neutropenic fever') to retrieve Klášterský et al. (2000), then citationGraph reveals 500+ citing works and findSimilarPapers uncovers CRASH extensions by Extermann et al. (2011). exaSearch('biomarkers in FN risk models') surfaces Bodey et al. (1966) leukocyte-infection links.
Analyze & Verify
Analysis Agent applies readPaperContent on Klášterský et al. (2000) to extract MASCC criteria, verifyResponse with CoVe cross-checks validation stats against Kuderer et al. (2006), and runPythonAnalysis computes pooled sensitivity (95% CI) from extracted tables using pandas. GRADE grading assesses MASCC evidence as high-quality for low-risk prediction.
Synthesize & Write
Synthesis Agent detects gaps like elderly-specific MASCC limitations via contradiction flagging across Extermann et al. (2011) and Klášterský et al. (2000); Writing Agent uses latexEditText for model comparisons, latexSyncCitations integrates 10 papers, and latexCompile generates a review section with exportMermaid flowchart of stratification pathways.
Use Cases
"Reanalyze MASCC score performance from validation datasets using Python"
Research Agent → searchPapers('MASCC validation datasets') → Analysis Agent → readPaperContent(Klásterský 2000) → runPythonAnalysis(ROC curves with scikit-learn on extracted AUC data) → matplotlib plot of sensitivity/specificity.
"Write LaTeX section comparing MASCC and CRASH for FN guidelines"
Synthesis Agent → gap detection(MASCC vs CRASH) → Writing Agent → latexEditText(draft comparison table) → latexSyncCitations(5 papers) → latexCompile(PDF with risk flowchart via exportMermaid).
"Find code implementations of neutropenic fever risk calculators"
Research Agent → searchPapers('MASCC calculator code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(R scripts for MASCC scoring) → runPythonAnalysis(test on sample patient data).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ FN models) → citationGraph → DeepScan(7-step verification with GRADE on MASCC validations). Theorizer generates hypotheses on biomarker-enhanced MASCC from Bodey (1966) and Maertens (2005). DeepScan chain verifies CRASH generalizability across Kuderer (2006) datasets.
Frequently Asked Questions
What is the MASCC Risk Index?
MASCC index by Klášterský et al. (2000) scores low-risk FN patients (≥21 points) using burden of illness (5 points), no hypotension (5), no COPD (4), solid tumor (4), no dehydration (3), outpatient status (3), age <65 (2); validated internationally with 1146 citations.
What methods are used in FN risk stratification?
Logistic regression-derived scores like MASCC (Klášterský et al., 2000) and CRASH (Extermann et al., 2011) combine clinical features, comorbidities, and lab values. Guidelines integrate them for management (Flowers et al., 2013; de Naurois et al., 2010).
What are key papers on this topic?
Foundational: Klášterský et al. (2000, MASCC, 1146 citations), Bodey et al. (1966, leukocytes-infection, 2475 citations). Impacts: Kuderer et al. (2006, FN costs, 1158 citations), Extermann et al. (2011, CRASH, 1113 citations).
What open problems exist?
Dynamic model updates for resistance (Averbuch et al., 2013), biomarker integration beyond MASCC (Maertens et al., 2005), and validation in diverse elderly cohorts (Extermann et al., 2011) remain unsolved.
Research Neutropenia and Cancer Infections with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Risk Stratification Models for Neutropenic Fever with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Neutropenia and Cancer Infections Research Guide